Talmadge E. King Jr, MD

Dean-SOM/VC-Medical Affairs

Dr. Talmadge E. King, Jr. was named dean of the UCSF School of Medicine and vice chancellor for medical affairs in May of 2015. He began his career at UCSF in 1997 as chief of Medical Services at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and Trauma Center. From 2006 to 2015, he served as chair of the UCSF Department of Medicine, the largest department in the school, with approximately 29 percent of the school's full-time faculty.

A physician-scientist, King’s research has focused on inflammatory and immunologic lung injury. He is best known for his pioneering work in the management of the interstitial pneumonias, a scarring process that often leads to death. His bibliography comprises more than 300 publications and he has co-edited eight books, including the acclaimed reference book, "Interstitial Lung Disease," now in its fifth edition.

King graduated from Gustavus Adolphus College and earned his medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver.

He is a member of the Institute of Medicine of the National Academy of Sciences, American Academy of Arts and Sciences, Association of American Physicians, American Clinical and Climatological Association and the Fleischner Society. He is a master of the American College of Physicians and fellow of the American College of Chest Physicians. He won the 2007 Trudeau Medal, the highest honor of the American Thoracic Society.

Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 1979 - Pulmonary/Critical Care, University of Colorado Medical Cente
Residency, 1977 - Internal Medicine, Emory University
M.D., 1974 - School of Medicine, Harvard University
Honors and Awards
  • 2016 APM Robert H. Williams, MD, Distinguished Chair of Medicine Award, Association of Professors of Medicine (APM), 2016
  • Breathing for Life Award, Foundation of the American Thoracic Society, 2012
  • Sesquicentennial Award, Gustavus Adolphus College, 2012
  • Fellow, American Academy of Arts and Sciences, 2011
  • Master, American College of Physicians, 2010
  • Alumni Citation, Gustavus Alumni Association, Gustavus Adolphus College, 2008
  • Trudeau Medal, American Thoracic Society, 2007
  • Member, Institute of Medicine, National Academy of Sciences, 2004
  • PAR Excellence Award, Public Advisory Roundtable of the American Thoracic Society, 2003
  • Member, Association of American Physicians, 1998
  • Elected honorary member, California Thoracic Society, 1998
  • Member. Colorado Pulmonary Hall of Fame, Colorado Thoracic Society, American Lung Association of Colorado, 1998
  • Member, The Fleischner Society, 1997
  • Member, Western Association of Physicians, 1993
  • James J. Waring Award For Outstanding Leadership in the Treatment of Lung Disease, American Lung Association of Colorado, 1992
  • Fellow, American College of Physicians, 1986
  • Fellow, American College of Chest Physicians, 1984
  • First Decade Award for Early Achievement, Alumni Association, Gustavus Adolphus College, 1980
  • Guild of St. Ansger Honor Society, Gustavus Adolphus College, 1970
Websites
Publications
  1. Crotty Alexander LE, Ware LB, Calfee CS, Callahan SJ, Eissenberg T, Farver C, Goniewicz ML, Jaspers I, Kheradmand F, King TE, Meyer NJ, Mikheev V, Shields PG, Shihadeh A, Strongin R, Tarran R. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda. 2020. PMID: 32243764


  2. Teherani A, Hauer KE, Fernandez A, King TE, Lucey C. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine. 2018. PMID: 29923892


  3. Lucey CR, Navarro R, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Lessons From an Educational Never Event. Volume 177 of Issue 10. 2017. PMID: 28846754


  4. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Collard HR, Lee JS. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Volume 152 of Issue 5. 2017. PMID: 28629914


  5. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE, Kim DS, Collard HR, Lee JS. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Volume 127. 2017. PMID: 28502419


  6. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE, Wolters PJ, Collard HR, Ley B. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Volume 72 of Issue 5. 2017. PMID: 28082530


  7. Sehgal NL, Neeman N, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process. Volume 92 of Issue 1. 2017. PMID: 27119329


  8. Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. A diagnostic model for chronic hypersensitivity pneumonitis. Volume 71 of Issue 10. 2016. PMID: 27245779


  9. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Volume 71 of Issue 5. 2016. PMID: 26968970


  10. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. Volume 3 of Issue 1. 2016. PMID: 26835133


  11. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Volume 47 of Issue 1. 2015. PMID: 26647432


  12. Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King TE, Travis WD. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Volume 35 of Issue 7. 2015. PMID: 26452110


  13. Assayag D, Kim EJ, Elicker BM, Jones KD, Golden JA, King TE, Koth LL, Shum AK, Wolters PJ, Collard HR, Lee JS. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Volume 109 of Issue 10. 2015. PMID: 26303338


  14. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Volume 148 of Issue 1. 2015. PMID: 25856121


  15. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Volume 109 of Issue 8. 2015. PMID: 26140806


  16. Hansell DM, Goldin JG, King TE, Lynch DA, Richeldi L, Wells AU. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Volume 3 of Issue 6. 2015. PMID: 25975761


  17. Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Volume 109 of Issue 7. 2015. PMID: 25956020


  18. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Volume 46 of Issue 1. 2015. PMID: 25900377


  19. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Volume 3 of Issue 5. 2015. PMID: 25890798


  20. Moodley Y, Corte T, Richeldi L, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Volume 20 of Issue 3. 2015. PMID: 25727967


  21. Costabel U, Albera C, Bradford WZ, Hormel P, King TE, Noble PW, Sahn SA, Valeyre D, du Bois RM. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Volume 31 of Issue 3. 2014. PMID: 25363219


  22. King TE, Noble PW, Bradford WZ. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Treatments for idiopathic pulmonary fibrosis. Volume 371 of Issue 8. 2014. PMID: 25147884


  23. Flaherty KR, Fell C, Aubry MC, Brown K, Colby T, Costabel U, Franks TJ, Gross BH, Hansell DM, Kazerooni E, Kim DS, King TE, Kitachi M, Lynch D, Myers J, Nagai S, Nicholson AG, Poletti V, Raghu G, Selman M, Toews G, Travis W, Wells AU, Vassallo R, Martinez FJ. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Smoking-related idiopathic interstitial pneumonia. Volume 44 of Issue 3. 2014. PMID: 25063244


  24. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Idiopathic pulmonary fibrosis: CT and risk of death. Volume 273 of Issue 2. 2014. PMID: 24927326


  25. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Volume 370 of Issue 22. 2014. PMID: 24836312


  26. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Volume 19 of Issue 5. 2014. PMID: 24836849


  27. . NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. Volume 370 of Issue 22. 2014. PMID: 24836309


  28. King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Volume 189 of Issue 7. 2014. PMID: 24476390


  29. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Volume 145 of Issue 4. 2014. PMID: 24114524


  30. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Volume 189 of Issue 2. 2014. PMID: 24160862


  31. Assayag D, Lee JS, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Rheumatoid arthritis associated interstitial lung disease: a review. Volume 74 of Issue 2. 2014. PMID: 24736263


  32. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Volume 19 of Issue 4. 2013. PMID: 24372981


  33. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Volume 108 of Issue 1. 2013. PMID: 24388667


  34. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Volume 43 of Issue 5. 2013. PMID: 24311766


  35. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Volume 270 of Issue 2. 2013. PMID: 24126367


  36. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Volume 188 of Issue 6. 2013. PMID: 24032382


  37. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen MLT, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Volume 144 of Issue 2. 2013. PMID: 23392130


  38. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Volume 14. 2013. PMID: 23848435


  39. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Volume 144 of Issue 1. 2013. PMID: 23370641


  40. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Volume 1 of Issue 5. 2013. PMID: 24429201


  41. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Volume 187 of Issue 11. 2013. PMID: 23725623


  42. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Volume 143 of Issue 6. 2013. PMID: 23732584


  43. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Prevalence and prognosis of unclassifiable interstitial lung disease. Volume 42 of Issue 3. 2012. PMID: 23222877


  44. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Volume 107 of Issue 2. 2012. PMID: 23186614


  45. Selman M, Pardo A, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Volume 186 of Issue 4. 2012. PMID: 22679012


  46. . NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. Volume 366 of Issue 21. 2012. PMID: 22607134


  47. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Volume 156 of Issue 10. 2012. PMID: 22586007


  48. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Volume 186 of Issue 1. 2012. PMID: 22561965


  49. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Volume 185 of Issue 10. 2012. PMID: 22505745


  50. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Volume 67 of Issue 5. 2012. PMID: 22426899


  51. King TE, Collard HR, Richeldi L. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Interstitial lung diseases. Preface. Volume 33 of Issue 1. 2012. PMID: 22365255


  52. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Volume 184 of Issue 12. 2011. PMID: 21940789


  53. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Volume 184 of Issue 4. 2011. PMID: 21616999


  54. King TE, Pardo A, Selman M. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Idiopathic pulmonary fibrosis. Volume 378 of Issue 9807. 2011. PMID: 21719092


  55. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Volume 184 of Issue 12. 2011. PMID: 21700909


  56. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Volume 377 of Issue 9779. 2011. PMID: 21571362


  57. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Volume 184 of Issue 1. 2011. PMID: 21474646


  58. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Volume 183 of Issue 6. 2011. PMID: 21471066


  59. King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Smoking and subclinical interstitial lung disease. Volume 364 of Issue 10. 2011. PMID: 21388315


  60. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Volume 183 of Issue 9. 2010. PMID: 21131468


  61. Ley B, Collard HR, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Volume 183 of Issue 4. 2010. PMID: 20935110


  62. Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE, Horne FM, Nayfield SG, Reynolds HY, Schmader KE, Toews GB, High KP. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Workshop on idiopathic pulmonary fibrosis in older adults. Volume 138 of Issue 3. 2010. PMID: 20822991


  63. Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. Volume 52 of Issue 6. 2010. PMID: 20523233


  64. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Volume 299 of Issue 1. 2010. PMID: 20418386


  65. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Volume 123 of Issue 4. 2010. PMID: 20362747


  66. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Volume 188 of Issue 2. 2010. PMID: 20069430


  67. Levinson W, King TE, Goldman L, Goroll AH, Kessler B. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Clinical decisions. American Board of Internal Medicine maintenance of certification program. Volume 362 of Issue 10. 2010. PMID: 20220192


  68. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Volume 65 of Issue 2. 2009. PMID: 19996335


  69. Kim EJ, Collard HR, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Volume 136 of Issue 5. 2009. PMID: 19892679


  70. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Volume 104 of Issue 2. 2009. PMID: 19815403


  71. Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE, Malhotra A, Parsons PE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. Volume 180 of Issue 4. 2009. PMID: 19661252


  72. King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Volume 374 of Issue 9685. 2009. PMID: 19570573


  73. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Volume 135 of Issue 6. 2009. PMID: 19255294


  74. King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Bosentan for idiopathic pulmonary fibrosis. Volume 9 of Issue 11. 2008. PMID: 18951296


  75. Kinder BW, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. Volume 177 of Issue 11. 2008. PMID: 18487622


  76. Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Müller NL, Nicholson AG, Raghu G, Selman M, Wells A. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Volume 177 of Issue 12. 2008. PMID: 18388353


  77. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Volume 133 of Issue 1. 2007. PMID: 18071016


  78. du Bois R, King TE. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Volume 62 of Issue 11. 2007. PMID: 17965079


  79. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Volume 177 of Issue 1. 2007. PMID: 17901413


  80. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Volume 102 of Issue 1. 2007. PMID: 17822892


  81. Kinder BW, Freemer MM, King TE, Lum RF, Nititham J, Taylor K, Edberg JC, Bridges SL, Criswell LA. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.., Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.., 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.., Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.., An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.., Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.., Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.., Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.., Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.., Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.., Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.., Prevalence and prognosis of unclassifiable interstitial lung disease.., Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.., A multidimensional index and staging system for idiopathic pulmonary fibrosis.., A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.., Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.., Interstitial lung diseases. Preface.., Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.., Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.., Idiopathic pulmonary fibrosis.., Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.., Smoking and subclinical interstitial lung disease.., Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.., Clinical course and prediction of survival in idiopathic pulmonary fibrosis.., Workshop on idiopathic pulmonary fibrosis in older adults.., Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.., Does chronic microaspiration cause idiopathic pulmonary fibrosis?., Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.., Clinical decisions. American Board of Internal Medicine maintenance of certification program.., The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.., Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.., The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.., Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.., Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.., Bosentan for idiopathic pulmonary fibrosis.., Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.., Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.., Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.., Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.., Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.., Acute exacerbations of idiopathic pulmonary fibrosis.., Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?., Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.., Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.., Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.., Respiratory bronchiolitis-interstitial lung disease: long-term outcome.., Clinical problem-solving. Anchors away.., Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?., Anticoagulant therapy and idiopathic pulmonary fibrosis.., Classification and natural history of the idiopathic interstitial pneumonias.., Current perspectives on the treatment of idiopathic pulmonary fibrosis.., Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.., Achieving diversity in academic internal medicine: recommendations for leaders.., A critical assessment of treatment options for idiopathic pulmonary fibrosis.., COPD: a dust-induced disease?., Idiopathic interstitial pneumonias: CT features.., The clinical course of patients with idiopathic pulmonary fibrosis.., High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.., Clinical advances in the diagnosis and therapy of the interstitial lung diseases.., Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.., Inequality in health care: unjust, inhumane, and unattended!., Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.., The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.., The case for diversity in academic internal medicine.., A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.., Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.., Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.., Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.., Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.., Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.., Demystifying idiopathic interstitial pneumonia.., Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.., Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.., Nonspecific interstitial pneumonia and systemic sclerosis.., Racial disparities in clinical trials.., Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.., Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Volume 56 of Issue 8. 2007. PMID: 17665457


  82. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.., How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.., Lessons From an Educational Never Event.., Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.., The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.., The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.., Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.., A diagnostic model for chronic hypersensitivity pneumonitis.., Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.., Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.., Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.., American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.., Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.., The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.., CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.., Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.., Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.., Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.., Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.., Treatments for idiopathic pulmonary fibrosis.., Smoking-related idiopathic interstitial pneumonia.., Idiopathic pulmonary fibrosis: CT and risk of death.., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.., Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.., All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.., Predicting survival across chronic interstitial lung disease: the ILD-GAP model.., Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.., Rheumatoid arthritis associated interstitial lung disease: a review.., Predictors of mortality in rheumatoid arthritis-related interstitial lung dis